IP Library Granted Patent US 9,994,823
Granted Patent B2
US 9,994,823 · App. 15/273,164 · Granted Jun 12, 2018

Purification of cell mixtures using molecular beacons targeting cell specific RNA

Inventors: Young Sup Yoon (Atlanta, GA); Gang Bao (Mableton, GA); Kiwon Ban (Dectaur, GA); Brian Wile (Grayson, GA)
Assignees: Emory University; Georgia Tech Research Corporation
C12N5/0657C12Q1/6881C12Q1/6888C12N2501/115C12N2501/155C12N2501/16C12N2501/999C12N2506/02C12N2506/45
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,994,823
App. No.
15/273,164
Granted
Jun 12, 2018
Kind
B2
Abstract

This disclosure is in the area of research and therapeutics. In certain embodiments, it provides methods to assist in the purification of cell mixtures, e.g., cardiomyocytes, using molecular beacons targeting cell-type specific RNA, e.g. mRNA.

Claims (16)

1. A kit comprising a molecular beacon comprising a loop sequence having SEQ ID NO: 2 and a fluorophore.

2. The kit of claim 1 further comprising instructions for purifying cardiomyocytes.

3. The kit of claim 1 further comprising bone morphogenetic protein 4.

4. The kit of claim 1 further comprising activin A.

5. The kit of claim 1 further comprising basic fibroblast growth factor.

6. The kit of claim 1 further comprising isoproterenol.

7. The kit of claim 1 , wherein the molecular beacon is enclosed in a container.

8. The kit of claim 7 , wherein the container is a vial or ampoule.

9. A method for purifying cardiomyocytes comprising,

a) introducing a molecular beacon comprising a loop sequence having SEQ ID NO: 2 into a mixture of cardiomyocytes and pluripotent stem cells under conditions such that the molecular beacon hybridizes to mRNA in the cardiomyocytes providing molecular beacon bound fluorescent cardiomyocytes; and

b) purifying the molecular beacon bound fluorescent cardiomyocytes by fluorescence activated cell sorting to provide a purified composition of cardiomyocytes.

10. The method of claim 9 , wherein the mixture of cardiomyocytes and pluripotent stem cells have been differentiated by a method comprising:

a) culturing undifferentiated stem cells under conditions such that a monolayer of the undifferentiated stem cells is formed,

b) applying bone morphogenetic protein 4 (BMP4), Activin A, and fibroblast growth factor 2 (FGF2) to the undifferentiated stem cells under conditions such that cardiac lineage cells are formed, and

c) treating the cardiac lineage cells with isoproterenol to generate spontaneous beating cardiomyocytes.

11. The method of claim 9 , wherein the pluripotent stem cells are mammalian pluripotent stem cells.

Assignments (1)
CONFIRMATORY LICENSE Recorded Jun 25, 2018
From: EMORY UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 046419/0275 →
Continuity (3)
Division 14211430 · Mar 14, 2014
Provisional Application 61787364 · Mar 15, 2013
Related Publication 20170002326A1 · Jan 5, 2017